Table 2

Comparative preclinical antitumor activity of BMS-275183 versus concomitantly evaluated paclitaxel

Tumor, s.c.Optimal treatment for BMS-275183aGross log cell kill (cures/total)
Schedule, RouteDoseBMS-275183Paclitaxel, i.v.
M109qd×5; 4, p.o.25b0.60.8
qd×5; 4, i.v.13 (20b)0.60.8
Mam 16/Cqd×5; 7, p.o.16b2.43.1
HCT-116q2d×5; 13, p.o.45b1.7(5/8)
q2d×5; 14, p.o.60b4.2(8/8)
qd×9; 14, p.o.32b3.6(8/8)
HCT/pkq2d×5; 15, p.o.45b0.91.0
A2780q2d×5; 13, p.o.65b4.45.8 (1/8)
q2d×5; 13, i.v.364.2 (1/7)(5/7)
qd×9; 14, p.o.36b(4/7)>4.5 (3/7)
A2780-ratq4d×3 10, p.o.6.5b0.7>4.2 (2/7)
q8d×2; 13, p.o.12(4/4)c8.3 (1/5)
q8d×2; 13, p.o.124.5 (2/7)3.1 (1/7)
  • a OD expressed in mg/kg/administration. Schedule of, e.g., qd×5 = one administration given daily consecutively for a total of five treatments or q2d×5 = every other day administration for five treatments. The number following the semicolon signifies the day of treatment initiation after tumor implant. There were usually seven or eight animals per treatment and control groups. Paclitaxel was administered i.v. either qd×5 (M109), q4d×3 (rat A2780) or q2d×5 (all other models).

  • b MTD reached (may be distinct from OD).

  • c Smaller (n = 4) than the typical group size used because of a lab error.